OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

Psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to infections. These symptoms can be difficult to manage, so OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis.

Study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.

Inclusion Criteria:

• Moderate to severe psoriasis
• Psoriasis affecting the fingernails

Exclusion Criteria:

• Previous treatment with Enbrel® (etanercept)
• Active infection
• Rheumatoid arthritis
• Any personal or family history of any neurologic demyelinating disease
• Receipt of investigational drugs or "biologics" within 4 weeks of the screening visit